The Goldman Sachs Group, Inc. vs AstraZeneca PLC
μκ°μ λ°λ₯Έ μκ°μ΄μ‘ λΉκ΅
The Goldman Sachs Group, Inc.
$255.0B
μμ #56
AstraZeneca PLC
$266.0B
μμ #52
μκ°μ λ°λ₯Έ μκ°μ΄μ‘
μ£Όμ μκ°
- The Goldman Sachs Group, Inc.μ΄(κ°) 2006λ κΉμ§ AstraZeneca PLCμ(λ₯Ό) μΆμνμ΅λλ€
- AstraZeneca PLCμ΄(κ°) 2008λ κΉμ§ The Goldman Sachs Group, Inc.μ(λ₯Ό) μΆμνμ΅λλ€
μ°λλ³ λΉκ΅
| μ°λ | The Goldman Sachs Group, Inc. | AstraZeneca PLC | μ λ |
|---|---|---|---|
| 2026 | $255.0B | $266.0B | AstraZeneca PLC |
| 2025 | $255.6B | $282.2B | AstraZeneca PLC |
| 2024 | $163.2B | $196.9B | AstraZeneca PLC |
| 2023 | $107.8B | $198.1B | AstraZeneca PLC |
| 2022 | $93.0B | $195.3B | AstraZeneca PLC |
| 2021 | $100.5B | $163.9B | AstraZeneca PLC |
| 2020 | $68.0B | $136.9B | AstraZeneca PLC |
| 2019 | $58.3B | $132.8B | AstraZeneca PLC |
| 2018 | $41.5B | $97.9B | AstraZeneca PLC |
| 2017 | $62.4B | $85.9B | AstraZeneca PLC |
| 2016 | $57.9B | $64.5B | AstraZeneca PLC |
| 2015 | $42.9B | $76.6B | AstraZeneca PLC |
| 2014 | $45.6B | $76.2B | AstraZeneca PLC |
| 2013 | $41.1B | $61.7B | AstraZeneca PLC |
| 2012 | $29.2B | $46.3B | AstraZeneca PLC |
| 2011 | $20.4B | $42.7B | AstraZeneca PLC |
| 2010 | $37.4B | $40.3B | AstraZeneca PLC |
| 2009 | $37.2B | $38.9B | AstraZeneca PLC |
| 2008 | $18.4B | $32.3B | AstraZeneca PLC |
| 2007 | $46.4B | $32.3B | The Goldman Sachs Group, Inc. |
| 2006 | $42.8B | $39.1B | The Goldman Sachs Group, Inc. |
| 2005 | $27.2B | $34.5B | AstraZeneca PLC |
| 2004 | $21.9B | $25.2B | AstraZeneca PLC |
| 2003 | $20.6B | $32.9B | AstraZeneca PLC |
| 2002 | $14.1B | $23.4B | AstraZeneca PLC |
| 2001 | $19.0B | $30.5B | AstraZeneca PLC |
| 2000 | $21.8B | $33.1B | AstraZeneca PLC |
| 1999 | $19.1B | $25.7B | AstraZeneca PLC |